We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
- Authors
Hirsch, Fred R.; Kerr, Keith M.; Bunn Jr, Paul A.; Kim, Edward S.; Obasaju, Coleman; Pérol, Maurice; Bonomi, Philip; Bradley, Jeffrey D.; Gandara, David; Jett, James R.; Langer, Corey J.; Natale, Ronald B.; Novello, Silvia; Paz-Ares, Luis; Ramalingam, Suresh S.; Reck, Martin; Reynolds, Craig H.; Smit, Egbert F.; Socinski, Mark A.; Spigel, David R.
- Abstract
Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC.
- Publication
Clinical Lung Cancer, 2018, Vol 19, Issue 4, p331
- ISSN
1525-7304
- Publication type
journal article
- DOI
10.1016/j.cllc.2018.03.014